Please assess the completion status of the following clinical trial:

Trial Title: Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Patients after surgical removal of histologically confirmed World Health Organization high-grade gliomas, including astrocytomas grade III (anaplastic astrocytoma), astrocytoma grade IV (glioblastoma multiforme, GBM), anaplastic oligodendroglioma and oligoastrocytoma~* Karnofsky performance status of greater or equal 60~* Patients who signed informed consent~* Patients can be receiving standard or investigational chemotherapy , hormonal therapy, immunotherapy or biologic agents as the primary treatment for their tumor~* Glucocorticoid therapy is allowed~* Bone marrow function (absolute neutrophil count \[ANC\] \>=1500/mm\^3 and platelet count \>=75,000/mm\^3); in the event of plate count dropping below 50,000/ mm\^3 the Boswellia will be withdrawn until plate count reaches 75,000 mm\^3 and above~* Liver function (bilirubin and alkaline phosphatase =\< 2 x normal and serum glutamic oxaloacetic transaminase \[SGOT\] =\< 3 x normal)~* Renal function (blood urea nitrogen \[BUN\] or creatinine =\< 1.5 x normal)~* Patients suffering from mild to moderate asthma, liver and kidney disease; an assessment of the condition will be made to establish a baseline and monitor progress at 4 weekly intervals to start with for the first two months and thereafter at the usual study intervals of 4 and 6 months; if there is any significant deterioration in their condition the Boswellia will be withdrawn until these parameters are restored to their pre-treatment levels~EXCLUSION CRITERIA:~* Any medical condition that could interfere with eating and oral administration of B. serrata~* Patients already taking herbal preparations that contain 5-LO inhibitors~* Any previous (within the past 3 years) or concurrent malignancies at other sites, with the exception of surgically cured carcinoma-in-situ of the cervix and non-melanoma skin cancer~* Pregnancy and breastfeeding~* Active infection~* Inability to be followed closely at the Cleveland Clinic Foundation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (intervention) (Type: EXPERIMENTAL): Patients receive oral Boswellia serrata extract 4 times a day and oral cyanocobalamin (vitamin B 12) once a day for 6 months in the absence of unacceptable toxicity.
- Arm II (control) (Type: ACTIVE_COMPARATOR): Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).